JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB312145

Alexa Fluor® 555 Anti-IMPDH2 antibody [EPR8365(B)]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal IMPDH2 antibody - conjugated to Alexa Fluor® 555.

View Alternative Names

IMPD2, IMPDH2, Inosine-5'-monophosphate dehydrogenase 2, IMP dehydrogenase 2, IMPD 2, IMPDH 2, Inosine-5'-monophosphate dehydrogenase type II, IMP dehydrogenase II, IMPDH-II

  • 578 PE

    PE Anti-IMPDH2 antibody [EPR8365(B)]

  • 660 APC

    APC Anti-IMPDH2 antibody [EPR8365(B)]

  • HRP

    HRP Anti-IMPDH2 antibody [EPR8365(B)]

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-IMPDH2 antibody [EPR8365(B)]

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-IMPDH2 antibody [EPR8365(B)]

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-IMPDH2 antibody [EPR8365(B)]

  • 603 Alexa Fluor® 568

    Alexa Fluor® 568 Anti-IMPDH2 antibody [EPR8365(B)]

  • 775 Alexa Fluor® 750

    Alexa Fluor® 750 Anti-IMPDH2 antibody [EPR8365(B)]

  • Unconjugated

    Anti-IMPDH2 antibody [EPR8365(B)]

  • Carrier free

    Anti-IMPDH2 antibody [EPR8365(B)] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR8365(B)

Isotype

IgG

Conjugation

Alexa Fluor® 555

Excitation/Emission

Ex: 555nm, Em: 565nm

Carrier free

No

Applications

Antibody Labelling, Target Binding Affinity

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

The immunogen used to raise this antibody shares 86% homology with Human IMPDH1. Cross-reactivity with this protein has not been confirmed experimentally.

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

IMPDH2 also known as inosine monophosphate dehydrogenase 2 plays an important role in the de novo synthesis of guanine nucleotides. This enzyme with a molecular mass of approximately 56 kDa catalyzes the conversion of inosine monophosphate (IMP) to xanthosine monophosphate (XMP) an important step in the nucleotide biosynthesis. IMPDH2 is expressed in various tissues across the body with high expression in proliferating cells due to increased nucleotide requirements.
Biological function summary

IMPDH2 functions as a homotetramer forming part of a larger complex that regulates nucleotide levels. This regulation is critical for cell growth differentiation and proliferation. IMPDH2 activity drives the synthesis of guanine nucleotides which are essential for DNA and RNA synthesis influencing cellular communication and energy transfer.

Pathways

The target IMPDH2 has a significant role in the purine nucleotide biosynthesis pathway aligning with other enzymes like GMP synthetase. This pathway is critical in maintaining cellular nucleotide pools. IMPDH2’s activity closely interacts with guanosine monophosphate reductase within the same pathway ensuring the balance between different types of nucleotides necessary for various cellular processes.

Aberrations in IMPDH2 activity link to immunological diseases and cancer. Overexpression or upregulation of this enzyme contributes to the rapid proliferation seen in cancerous cells by maintaining high guanine nucleotide levels. Additionally IMPDH2 serves as a target for immunosuppressive drugs used in autoimmune conditions highlighting its relationship with T- and B-cell proliferation. This positions IMPDH2 in therapeutic strategies alongside its pathway partners to modulate disease outcomes.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth (PubMed : 7763314, PubMed : 7903306). Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism (PubMed : 14766016). It may also have a role in the development of malignancy and the growth progression of some tumors.
See full target information IMPDH2

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com